



# H446



**Figure S1.** Bioinformatic Analysis of RNA SEQ Predicts a Shift toward a MET Phenotype with Acquired Resistance to MTI-101 in H446 vs. H446-R. EMT genes' fold change between H446 and H446-R; SPARC-FDR =  $33.09 \times 10^{-4}$ , VIM-FDR =  $6.36 \times 10^{-4}$ , FN1- FDR =  $2.81 \times 10^{-4}$ , TWIST1- FDR =  $1.60 \times 10^{-4}$ .

Figure 3A (N=2)

S2




TWIST1 N=2



B-Actin N=2


S3

Figure 3A (N=1)



S4

Figure 3A (N=3)



Figures S2–S4. Original Western blots of TWIST1 ( $n = 3$ ).

S5

Figure 3C (N=1)




Figure 3C (N=2)

S6





Figure 3C (N=3)

S7



Figures S5–S7. Original Western blots of TWIST2 ( $n = 3$ )

Figure 4A (N=1)

S8




Figure 4A (N=2)

S9





Figure 4A (N=3)



Figures S8–S10. Original Western blots for Figure 4A ( $n = 3$ )

Figure 4G







Figure S11. Original Western blot of Figure 4G.



**Figure S12.** H446 In Vivo Single Treatment MTI-101. (A) B-catenin localized heavily inside the cell in the one kidney of the control group with B-catenin presence. (B) A representative image of the treatment group containing B-catenin almost exclusively extracellularly.



**Figure S13.** All H446 In Vivo H&E and IHC Images at 4x Magnification. Kidneys were taken from the H446 in vivo study, fixed in formalin, paraffin blocked and then sliced for slides to analyze EMT markers. Three control and three treatment (10 mg/kg MTI-101) mice were picked at random to compare EMT markers. (A) H&E, (B) E-cadherin, (C) vimentin, (D) B-catenin.



**Figure S14.** Representative IVIS Images of Tumor Location for each In Vivo Study.